MOVENTIG

MOVENTIG Tolerability

MOVENTIG has been shown to be generally well-tolerated in patients with non-cancer pain and OIC for up to 52 weeks.²

In the pooled data from clinical trials, the most commonly reported adverse reactions with naloxegol (≥5%) were: abdominal pain, diarrhoea, nausea, headache and flatulence. The majority of gastrointestinal adverse reactions were graded as mild to moderate, occurred early in treatment and resolved with continued treatment. They were often reported as having a component of cramping discomfort.¹

Frequency categories are defined according to the following conventions:

• very common (≥ 1/10)
• common (≥ 1/100 to < 1/10)
• uncommon (≥ 1/1,000 to < 1/100)
• rare (≥ 1/10,000 to < 1 /1,000)
• very rare ( < 1/10,000)
• not known (cannot be estimated from the available data)

* Definition of laxative inadequate responder (LIR): In the two weeks prior to first study visit patients had to have reported concurrent OIC symptoms of at least moderate severity while taking at least one laxative class for a minimum of four days during the pre-study period.¹